SOURCE: StockCall


March 28, 2011 09:25 ET

Opinions on Biogen Idec Inc. and Genzyme Corp. -- Biotech Industry Focusing on R&D and M&A

JOHANNESBURG, SOUTH AFRICA--(Marketwire - March 28, 2011) - offers investors comprehensive research on the Biotechnology industry and has completed analytical research on Biogen Idec Inc. (NASDAQ: BIIB) and Genzyme Corp. (NASDAQ: GENZ). Register with us today at to have free access to these researches. 

The Biotechnology Industry has been garnering a lot of attention recently, as large pharmaceutical companies have been looking for ways to increase their product lines, develop new products and fill in revenues lost by the large number of expiring patents that are occurring. Mergers and acquisitions have been a hot topic in the industry, with companies such as Genzyme Corp., receiving an offer from Sanofi-Aventis to purchase all outstanding shares. All board of director members for Genzyme have advised shareholders to accept. Investors looking for free research on Genzyme Corp. are welcome to sign up at is an online platform where investors doing their due-diligence on the Biotechnology industry can have easy and free access to our analyst research and opinions on Biogen Idec Inc. and Genzyme Corp.; all investors need to do is register for a complimentary membership at

On the research and development side of things, companies like Biogen Idec Inc. have been focusing their attentions on developing new products and bringing those in the pipeline to market. The company has a number of neurology, oncology and immunology products in various stages of development. Investors looking for free research on Biogen Idec Inc. are welcome to sign up at

As large pharmaceutical companies look to increase their holdings and the global population looks for new treatments, companies in the Biotechnology industry continue in their efforts to succeed. Register now at to have free access to our reports on the Biotechnology industry.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information